Grow Brian's most recent trade in Organogenesis Holdings Inc - Ordinary Shares - Class A was a trade of 189,369 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 189,369 | 189,369 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 183,067 | 670,490 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 19,423 | 490,827 (0%) | 0% | 3.7 | 71,865 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 10,559 | 510,250 (0%) | 0% | 3.7 | 39,068 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 2,748 | 488,079 (0%) | 0% | 3.7 | 10,168 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 656 | 487,423 (0%) | 0% | 3.7 | 2,427 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 01 Apr 2024 | 1,977 | 520,809 (0%) | 0% | 2.8 | 5,536 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 313,636 | 313,636 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Grow Brian | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 173,469 | 522,786 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 18,738 | 353,462 (0%) | 0% | 3.7 | 68,956 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 3,346 | 350,116 (0%) | 0% | 3.7 | 12,313 | Class A Common Stock |
| Organogenesis Holdings Inc... | Grow Brian | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.48 per share. | 15 Feb 2024 | 799 | 349,317 (0%) | 0% | 3.5 | 2,781 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.13 per share. | 01 Apr 2023 | 2,408 | 372,200 (0%) | 0% | 2.1 | 5,129 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 345,470 | 345,470 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 291,009 | 374,608 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.92 per share. | 15 Feb 2023 | 3,346 | 84,398 (0%) | 0% | 2.9 | 9,770 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 Feb 2023 | 799 | 83,599 (0%) | 0% | 2.7 | 2,197 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.46 per share. | 20 Aug 2022 | 805 | 87,744 (0%) | 0% | 1.5 | 1,175 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2022 | 805 | 0 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.89 per share. | 01 Apr 2022 | 1,977 | 86,939 (0%) | 0% | 7.9 | 15,599 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 107,063 | 107,063 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 45,143 | 89,715 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 15 Feb 2022 | 799 | 88,916 (0%) | 0% | 7.8 | 6,216 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.83 per share. | 01 Apr 2021 | 1,977 | 44,572 (0%) | 0% | 19.8 | 39,204 | Class A Common Stock |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 82,556 | 82,556 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | Brian Grow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 10,782 | 46,549 (0%) | 0% | 0 | Class A Common Stock |